Incubation with high dotes of tritiated thymidine in vitro was used to determine the percent of progenitor cells in the S phase of the cell cycle. Peripheral blood (PB), bone marrow (BM), and spleen populations from mice injected with granulocyte colony-stimulating factor (G-CSF) at 5 pg/day for 5 days and BM cells from uninjected Viermates were assayed. Although the percentage of progenitor cells in S phase in the marrow (47% f 50/0) and spleen (5240 f 9%) was increased significantly in G-CSF-treated mice, only a small proportion of PB progenitor cells (PBPC) were in S phase (7% f 4%). In normal human subjects injected with G-CSF at 5 or 10 pg/ kgld, the proportions of PB myeloid (-1 f 4%) and erythroid T HE ABILITY OF CYTOIUNES with or without chemotherapy to dramatically elevate levels of stem and progenitor cells in the peripheral blood (PB) is now well establi~hed,"~ as is the clinical value of such population^.^-^ However, the mechanisms by which progenitor cells are mobilized by cytokines to enter the blood are unknown, as is the question of whether these mechanisms represent the normal process of cell release to the blood during basal hematopoiesis. PB progenitor cells (PBPC) are not a representative sample of progenitor cells either in the bone marrow (BM) or spleen? Furthermore, whereas clinical studies clearly show more rapid hematopoietic reconstitution with PBPC transplantation than seen with BM transplantation:6-8,10 analysis of the same cells by clonal culture shows a marked deficiency in the most mature progenitor cells (day 7 colony-forming cells [CFC]) relative to resting BM."
T HE ABILITY OF CYTOIUNES with or without chemotherapy to dramatically elevate levels of stem and progenitor cells in the peripheral blood (PB) is now well establi~hed,"~ as is the clinical value of such population^.^-^ However, the mechanisms by which progenitor cells are mobilized by cytokines to enter the blood are unknown, as is the question of whether these mechanisms represent the normal process of cell release to the blood during basal hematopoiesis. PB progenitor cells (PBPC) are not a representative sample of progenitor cells either in the bone marrow (BM) or spleen? Furthermore, whereas clinical studies clearly show more rapid hematopoietic reconstitution with PBPC transplantation than seen with BM transplantation:6-8,10 analysis of the same cells by clonal culture shows a marked deficiency in the most mature progenitor cells (day 7 colony-forming cells [CFC] ) relative to resting BM."
Progenitor cells detected by clonal in vitro cultures are not likely to be major contributors to the cells repopulating a graft recipient on a long-term basis. However, it is still of importance to establish their properties, particularly their cell cycling status, when tumor cell purging or retroviral insertion of genes might be contemplated. We have undertaken an assessment of the cell cycle status of PBPC mobilized by granulocyte colony-stimulating factor (G-CSF) and other cytokines. The data indicate that only a small minority of PB progenitors (either steady-state or cytokine-mobilized) is in W O f 8%) progenitor cells in S phase were very low compared with the proportion of myeloid progenitor cells in S phase in normal BM (34% f 10%). Similarly, the large majority of steady-state PBPC and PBPC mobilized by interleukin-3 in combination with either granulocyte-macrophage colonystimulating factor or G-CSF were also found not to be in S phase. Experiments indicated that the low percentages of PBPC in S phase were not ascribable either to inhibitory elements in the blood or to reduced responsiveness to growth factors. 0 1995 by The American Society of Hematology.
S phase. The noncycling status of these cells is not due to inhibitory substances in the blood or to hyporesponsiveness of the progenitor cells to growth factors.
MATERIALS AND METHODS
Human subjects and cytokine mobilization protocols. Specimens of PB and BM were collected from (1) normal volunteers participating in a phase MI clinical trial of G-CSF as a mobilizing agent of progenitor cells, (2) normal donors at the time of BM harvest for allogeneic transplantation, or (3) cancer patients enrolled in a clinical trial of interleukin-3 (E-3) and other cytokines as mobilizing agents for progenitor cells. Each protocol was approved by the Institutional Ethics Committee of the Royal Melbourne Hospital and all subjects gave written informed consent.
Recombinant human G-CSF (Filgrastim; Amgen, Thousand Oaks, CA) was administered to normal volunteers as a daily subcutaneous injection of 5 or 10 pg/kg/day for up to 10 days. Cancer patients received daily subcutaneous injections of recombinant human IL-3 (Sandoz, Basel, Switzerland) at 2.5 01 5 pg/kg/d and either recornbinant human granulocytemacrophage colony-stimulating factor (GM-CSF; Leucomax; Sandoz) at 5 pg/kg/d or G-CSF at 5 p@g/ d for 7 days.
Mice. BALBlc mice were reared in specific pathogen-free conditions and used at 8 weeks of age when their weight was approximately 25 g. G-CSF (Lenograstim; Amrad, Melbourne, Australia) at 5 pg/kg/day (200 pg/kg/d) was injected subcutaneously twice daily for 5 days, as previously described.'
Preparation of cells. Hematopoietic cells were collected from the blood, BM, and spleen of mice as previously described.' For each experiment, cell suspensions from each organ were pooled from two or three mice. In some cases, pooled blood or marrow suspensions were subjected to density separation (density, 1.077 g/ dL; Ficoll-Paque; Pharmacia, Uppsala, Sweden) at 400g for 20 minutes. Light-density cells from the interface were then collected and washed three times before use. Alternatively, PB cells were used after washing only.
Heparinized PB samples and BM aspirates from human subjects were routinely fractionated by density centrifugation as described above. After three washes, light-density cells were resuspended in Iscove's modified Dulbecco's medium (IMDM) with 10% fetal calf serum (FCS) (voVvo1). Viable cell counts were performed using hemocytometers and eosin staining.
En vivo incubation of cells. In some experiments, freshly fractionated blood cells were incubated at 37°C in 10% FCS/medium containing G-CSF at 10 n g / d for 2 hours (murine cells) or 3 hours (human cells). The entire cell suspension was then washed twice in medium alone, resuspended in 10% FCSlmedium, and divided into For personal use only. on September 24, 2017. by guest www.bloodjournal.org From l-mL aliquots for cell cycle assays. Murine cells were also incubated in autologous plasma (removed before cell fractionation) before being washed and assayed.
Dose-response experimenfs. Murine BM cells from normal mice and PB, marrow, and spleen cells from their G-CSF-treated littermates were cultured for 7 days in agar using serial twofold dilutions of G-CSF at 10 ng/mL, recombinant murine GM-CSF (Schering, Kenilworth, NJ) at 6 ng/mL, or recombinant murine IL-3 (Peprotech, Rocky Hill, NJ) at 10 ng/mL. G-CSF-stimulated cultures were initiated using 100,OOO cells from each organ. In cultures involving other types of stimulation, 50,000 marrow cells or 75,000 spleen cells were used.
Tritiated thymidine suicide assay for S-phase analysis. In vitro 'H thymidine suicide assays of progenitor cells were performed following the technique of Broxmeyer et a1,'2." with some modifications. Briefly, cells were incubated at 37°C for 20 minutes (murine cells) or 30 minutes (human cells) in the presence of 50 pL of 'H thymidine (1 mCi/mL; specific activity, 26 Ci/mmoVL) or an equal volume of medium (Dulbecco's modified Eagle's medium for murine cells or IMDM for human cells). Immediately after incubation, the cells were washed with 2,000 pg of thymidine in 4 mL of ice-cold medium. After two further washes with medium alone, the cells were resuspended in 1 mL of 10% FCS/medium. A total of 0.5 mL of each suspension was then added to medium containing a final concentration of 0.3% agar. Triplicate or quadruplicate l-mL cultures were prepared and, after gelling, incubated for 7 days in a fully humidified atmosphere of air and 10% CO, for murine cells and 7 or 14 days in 5% C02/air for human cells. In many experiments, Sphase specificity of progenitor cell killing was controlled for by parallel incubations of cells in 'H thymidine plus 500 pg thymidine or 500 pg thymidine alone, which uniformly gave similar results to the medium-only incubated cells. Within each experiment, positive controls for 'H thymidine killing were included. Cell cycling assays were routinely commenced immediately after the collection of murine specimens or within 2 hours of the collection of human specimens.
Clonal cultures. One-milliliter agar cultures for murine hematopoietic cells were established as previously described.I4 Pokeweed mitogen-stimulated spleen-conditioned medium (SCM)I4 was used as the stimulus for all murine cultures. For l-mL cultures of human cells, the following combinations of growth factors were used: G-CSF at 500 U, GM-CSF (Amgen, Thousand Oaks, CA) at 100 ng, and recombinant human stem cell factor (SCF Amgen) at 100 ng to assay day-l4 granulocyte-macrophage colony-forming cells (GM-CFC); G-CSF and GM-CSF to assay day-7 GM-CFC; and GM-CSF, SCF, IL-3 (Amgen) at 100 ng, and recombinant human erythropoietin (Epo; Amgen) at 4 U to assay day-l4 burst-forming units-erythroid (BFU-E). Using standard criteria,14 the numbers of colonies per culture were counted at 35 X magnifications using a dissection microscope. In the majority of experiments, cultures were scored in a coded fashion to minimize possible observer bias.
Cultures were also fixed and stained as previously described to identify the cellular composition of c o l o n i e~.~~'~ The number of cells used to initiate each type of culture was adjusted to result in between 15 and 100 colonies per culture in the control cultures. In murine experiments, PB was cultured at a concentration of 50,000 lightdensity cells or 10 pL/mL, and BM and spleen cells at 50,000 cells/ mL. In human experiments, cultures were initiated with 20,000 BM celldml, 100,000 to 200,000 steady-state PB cells/mL, 25,000 G-CSF-mobilized PB celldml, or 40,000 to 50,000 IL-3 combinationmobilized PB cells/mL.
Calculation of S-phase fraction. The proportion of CFC in S phase for each cell suspension was calculated using the following formula: 
RESULTS
Progenitor cell cycling in G-CSF-treated mice. After 5 days of G-CSF injections, the proportions of cells in S phase of BM (47% 2 5%) and splenic (52% 2 9%) progenitor cells were significantly greater than for progenitor cells from uninjected control mice (39% -C 6.5% ; Fig l) . In sharp contrast, the proportion of progenitor cells in S phase in the blood from the same G-CSF-treated mice was markedly lower (7% 2 4%). This result for PB cells was not an artefact of the processes used to prepare the cells for assay, nor was it simply attributable to the presence of inhibitors in the blood. Results of experiments using washed unfractionated blood cells (8% t 7% in S phase; n = 2) were similar to results of experiments using light-density mononuclear cells (6% t 3% in S phase; n = 5). Control experiments comparing the S-phase fractions of washed or light density-fractionated, BM samples from both uninjected or G-CSF-injected mice showed equivalence. Similarly, when BM cells were mixed with fresh blood from uninjected mice, no perturbation was observed of the percentage of marrow progenitor cells in S phase ( Table 1) .
The use of SCM (containing GM-CSF and IL-3)I4 as the stimulus enabled the enumeration of progenitor cells of six nonerythroid lineages as defined by cellular composition of the colonies at 7 days. In cultures of PB, neutrophil-CFC, GM-CFC, macrophage-CFC, eosinophil-CFC, blast-CFC, and megakaryocyte-CFC were present in equal numbers in 'H thymidine-treated cultures and in control cultures. In parallel analyses of the BM and spleen cultures from G-CSFtreated mice and BM cultures from normal mice, significant 'H thymidine killing was observed with each progenitor cell type.
Progenitor cell cycling in cytokine-treated humans. Figure 2 shows the proportion of myeloid progenitor cells in S phase in the BM and PB of untreated subjects, in the blood of G-CSF-injected subjects, and in the blood and BM of subjects receiving combinations of IL-3 and GM-CSF or G-CSF. AS was observed with murine cells, progenitor cells in the blood displayed a very low or negative percentage of cells in S phase and the cells appeared not to be cycling. This was clearly distinct from the behavior of BM progenitor cells, of which, in agreement with the results of other studmost mature progenitor cells assayable in the BM (day-7 CFC) were markedly underrepresented in the blood from CSF-injected subjects compared with the marrow and the low numbers of cells prevented satisfactory estimates of the percentage of cells in S phase.
Erythroid progenitors able to produce day-14 BFU-E were also analyzed for cycling status. Consistent with the GMies,15.16 30% to 60% were observed to be in S phase. The CFC results, circulating erythroid progenitor cells mobilized by G-CSF for 3 or 5 days showed minimal S-phase killing by 3H thymidine (0% +-8%; n = 4). For 1 patient receiving GM-CSF and IL-3 for 7 days, parallel analyses on erythroid colonies from PB (3% S phase) and BM (26% S phase) again gave similar results to those observed for myeloid progenitors.
Neither the duration of in vivo G-CSF treatment nor the particular in vivo cytokine treatment used altered the finding that only a negligible fraction of circulating progenitor cells was in S phase. It was of interest that myeloid progenitor ROBERTS AND METCALF cells in the blood of untreated subjects also appeared not to be in cycle.
PBPC are normo-responsive to cytokines. The possibility that progenitor cells in the blood might be functionally distinct from those in the BM and spleen in terms of their responsiveness to cytokines was explored in experiments using three CSFs. Figure 3 shows that, in 7-day agar-culture assays, cells in the blood displayed similar responsiveness to stimulation to their counterparts in the marrow and spleen.
The consequences of briefer (2 to 3 hours) exposure to growth factors were explored by in vitro incubation of mobilized PBPC with G-CSF in optimal concentration and in murine experiments with plasma from G-CSF-treated mice before 'H thymidine assay. The results ( Table 2 ) indicated a significant increase in the S-phase fraction of PBPC after incubation with growth factors. No significant increases were observed when fractionated cells were incubated in parallel with 10% FCS/medium alone. Similar experiments were performed with progenitor cells present in steady-state human blood. After incubation with G-CSF, the S-phase fractions were estimated as 3%, 17%, and 24% in three independent experiments (Table 2) .
DISCUSSION
The present study documents that the hematopoietic progenitor cell populations mobilized into the PB by G-CSF are not actively cycling. Few, if any, circulating progenitor cells in humans were in S phase, whereas in mice only a minor fraction of cells incorporated 'H thymidine. This finding is surprising because a major function of hematopoietic growth factors is to deliver a proliferative signal that accelerates the progression of responding cells through G, into S The data shown are colony counts from representative experi- For For Standen et aIz2 reported sensitivity to a 2-hour exposure to hydroxyurea in 23% of PBPC. However, the latter result was significantly reduced in comparison to normal BM cells (39% in S phase), suggesting perhaps that, rather than being deeply quiescent (Go), many of the circulating progenitors might have been in a prolonged G, phase and might enter S phase with time, particularly if exposed to growth factors.
Recently, To et a123 reported a detailed flow cytometric analysis of PBPC mobilized by chemotherapy alone, chemotherapy plus cytokines, and cytokines alone. CD34+ cells from each mobilization strategy were found to have uniformly low CD71 expression and to retain little Rhodamine 123, suggesting that these cells were metabolically quiescent and probably not in cell cycle. These observations are entirely in accord with our direct S-phase analysis. Taken together, they indicate that PBPC, whether at steady state or after induction with cytokines, are not in cell cycle.
It is intriguing that the expanded PB population of progenitors after cytokine therapy should be noncycling, whereas progenitor cells in the marrow (and spleen in mice) are maximally proliferating. We have previously shown that, although the PB progenitor pool is increased several hundredfold in mice injected with G-CSF, this population is still only a very minor component (<2%) of the total body progenitor pool.' It may be, therefore, that a quite selective release occurs of noncycling progenitor cells from the marrow into the blood.
The possibility that inhibitory factors in the blood simply put cells out of cycle was excluded by two experiments. Firstly, mixing experiments of BM and unfractionated PB showed no reduction in the proportion of cells in S phase. Secondly, incubation of PBPC in plasma from G-CSF-injected mice for 2 hours was shown to stimulate the entry of a significant proportion of cells into S phase. We also explored the possibility that the noncycling status of circulating progenitor cells might have been due to refractoriness to stimulation by growth factors. However, PBPC from G-CSF-treated mice showed a responsiveness to stimulation by G-CSF, GM-CSF, or IL-3 that was identical with that of cells from the BM and spleen of the same animals and from normal BM. Furthermore, with both murine and human cells, a short incubation of PB cells with G-CSF resulted in the recruitment of 16% to 20% of progenitors into S phase. A similar result was also shown for progenitor cells from human steady-state PB. Together, these results suggest that circulating progenitor cells have unaltered responsiveness to growth factors and that at least some of the quiescent cells can rapidly transit G, in the presence of these factors.
No explanation is available at present for why few CSFmobilized PB progenitor cells are in S phase. Data have been published indicating that release of progenitor cells from the marrow is a selective process that could be highly comple~."'~ Two possible explanations for the deficit in S-phase cells are ( I ) that there may be a selective release of cells immediately after mitosis, leading to a biased population either in Go or early G,, and/or (2) that cells about to enter S phase are cleared from the circulation possibly after the expression of critical adhesion molecules. These two processes are not mutually exclusive, but the second process would result in progenitor cells having a quite short halflife in the circulation.
The absence of S phase cells from PB populations mobilized by cytokines needs to be kept in mind in attempts to selectively kill tumor cells ex vivo in such populations and in attempts to transfer genes using retroviral vectors. Because the cells readily enter S phase after CSF stimulation in vitro, the addition of CSFs to harvested PB cells presumably needs to be avoided during tumor cell killing procedures but needs to be used in attempted retroviral insertion of genes.
